Clinical Trial Update: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity [Phase 3]

View source ↗

Summary

Phase 3 trial update reports on semaglutide's effects on cardiovascular outcomes (heart disease and stroke) in adults with overweight or obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Ischemic Heart Disease
• Obesity
• Stroke

Drugs mentioned

• OZEMPIC (semaglutide)
• WEGOVY (Semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Overweight, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2024-08-30